Market Overview

I think you’ll love what you hear,
what you’ll see and the opportunities
that will be set before you.
- Jon Najarian

Saama Technologies and ICON Commercialization and Outcomes Partner to Unlock the Value of Real World Evidence (RWE)


ICON's Late Phase Experts to Leverage Saama's Award-Winning Life Science
Analytics Cloud to Support Improved Commercial Decision Making

, a leading clinical and health data analytics company,
and ICON
(NASDAQ:ICLR), a global provider of drug development and
commercialization solutions and services, have partnered to accelerate
the use of Real World Evidence (RWE) across the product lifecycle and
drive mission critical decisions for medical affairs, reimbursement and
commercialization functions.

Biopharmaceutical, medical device and diagnostic companies are seeking
comprehensive RWE technology solutions that can support an array of RWE
applications across the enterprise. Through this partnership, ICON
brings real world data (RWD) strategy and platform deployment expertise
to complement Saama's deep experience in utilizing innovative
applications such as Natural Language Processing, Machine Learning and
advanced Data Visualization tools.

The volume of healthcare data continues to grow exponentially and is
forecasted to hit more than two zettabytes by 2020.* This dramatic
increase in the availability of and access to anonymized electronic
patient records requires new approaches for closing the medical product
development and commercialization cycle.

"Saama is very excited about our partnership with ICON, which further
expands our new Life Science Ecosystem," said Murali Krishnam, VP
Strategic Partnerships and Alliances of Saama. "Saama's Artificial
Intelligence-based analytics platform, combined with ICON's Real World
Evidence, Strategy and Analytic (RWESA) services, will help
biopharmaceutical, medical device and diagnostics companies rapidly
deploy a RWE-generating platform. This will support greater efficiencies
in drug development, providing the RWE needed to inform medical affairs,
regulatory and reimbursement decisions and underscoring the value of the
medical technology to patients and providers."

"Our partnership with Saama will help us to unlock the real world data
for our sponsors, offering improved clarity regarding the various types
of real world data and how they can best generate RWE to inform clinical
and commercialization strategies," said Ramita Tandon, Executive Vice
President of ICON's Commercialization and Outcomes Division.

Saama's award-winning Life
Science Analytics Cloud
(LSAC) integrates multiple sources of
structured, unstructured and real-time data to optimize clinical and
commercialization processes for deployment in less than 90 days, thus
securing better business outcomes faster. In addition, LSAC further
lowers the total cost of platform ownership significantly for continuous
RWE generation and for managing evolving business needs. This approach
integrates seamlessly with ICON's unique Real World Intelligence™
approach to combine RWD and advanced expertise in answering important
questions on patient experience, market access requirements, strategic
evidence planning and roadmap development.

Through this partnership, ICON becomes part of Saama's recently
announced Life
Science Ecosystem
, which combines the unparalleled benefits of
Saama's Life Science Analytics Cloud with the specific strengths of
clinical or real-world data providers.

For information about joining Saama's Life Science Ecosystem, or to
schedule a demonstration of Saama and ICON's RWE data analytics
solutions, visit

About Saama

Saama Technologies is the advanced data and analytics company delivering
actionable business insights for life
and the Global 2000. Saama is singularly focused on driving
fast, flexible, impactful business outcomes for its clients through
advanced data and analytics. Saama's unique "hybrid" approach integrates
focused solutions and expertise across the life sciences domain,
business consulting, machine learning, automated data management, cloud
and big data technologies. Saama's approach integrates manual and
disconnected data initiatives into a well-aligned roadmap facilitating
the client's journey from strategy through solution implementation to
generate business outcomes.

About ICON

ICON plc is a global provider of outsourced drug development and
commercialisation solutions and services to pharmaceutical,
biotechnology, medical device, and government and public health
organisations. The company specialises in the strategic development,
management and analysis of programs that support clinical development -
from compound selection to Phase I-IV clinical studies. With
headquarters in Dublin, Ireland, ICON currently, operates from 97
locations in 38 countries and has approximately 13,380 employees.
Further information is available at

*The Digital Universe Driving Data Growth in Healthcare, EMC Corp.
Vertical Industry Brief with Research and Analysis by IDC, 2014

View Comments and Join the Discussion!